PO.ET07.02 · 实验与分子治疗
Micronuclei (MN) dynamics in preclinical models and in patient reticulocytes as a pharmacodynamic biomarker for the first in class DNA polymerase theta (PolΘ) inhibitor ART6043
该海报暂无可访问的完整资料
AACR 官方页面 ↗
作者与单位
摘要 Abstract
Introduction: ART6043 is a first in class, potent and selective polymerase domain inhibitor of DNA Polθ, a central mediator of the microhomology‑mediated end joining (MMEJ) DNA double strand break (DSB) repair pathway. Novel biomarkers are important to demonstrate target engagement of ART6043. Polθ knock out mouse studies highlighted increased levels of MN in mouse reticulocytes (RETs) and normochromatic erythrocytes since MN are a common hallmark of genome instability. Here we describe the utility of an assay designed to monitor MN induction in reticulocytes from both preclinical models and patient samples to evaluate Polθ inhibition.
Methods: This analysis builds on the MN-RETs assay, which is traditionally used as a preclinical toxicology assessment (Tometsko et al., 1995). This assay involves fixing whole blood, isolating reticulocytes (specifically in the human assay), and labelling them for nucleic acids to stain any MN. High throughput flow cytometry is then used to quantify the number of reticulocytes with MN.
Results: These data demonstrated the utility of MN-RET as a target engagement biomarker for ART6043 in preclinical studies and in the subsequent clinical study (NCT05898399). In preclinical xenograft models ART6043 monotherapy and ART6043 in combination with olaparib induces MN-RET at doses where tumor regressions occurred. The MN-RET data evaluated in the phase 1 trial of ART6043 mirrored the preclinical data. Patients treated with the highest dose of ART6043 evaluated as monotherapy had elevated MN-RETs, while patients treated with ART6043 in combination with olaparib had statistically higher MN-RET levels. This suggests that the combination of two DNA repair pathway inhibitors, targeting separate mechanisms, leads to a synergistic increase in DNA damage.
Summary: The increase in MN-RETs observed in patients dosed with ART6043 has demonstrated target engagement of a Polθ inhibitor for the first time in humans. MN-RETs has demonstrated potential utility as a mechanism of action target engagement biomarker for a range of therapeutics targeting different DNA damage repair pathways.
References: Tometsko, A. M., Dertinger, S. D., & Torous, D. K. (1995). Analysis of micronucleated cells by flow cytometry. 4. Kinetic analysis of cytogenetic damage in blood. Mutation Research/Environmental Mutagenesis and Related Subjects , 334 (1). https://doi.org/10.1016/0165-1161(95)90025-X
利益披露 Disclosure
C. L. Baxter,
Artios Pharma Employment, Stock Option.
T. A. Yap,
University of Texas MD Anderson Cancer Center Employment.
Acrivon, Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint, Bristol Myers Squibb, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline ).
Genentech, Haihe, Ideaya ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi ).
Scholar Rock, Seattle Genetics, Tango, Tesaro, Vivace, and Zenith ).
NCI Cancer Center Support, Department of Defence, V Foundation Scholar Grant, NIH ).
AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, BeiGene, BioCity Pharma, Blueprint, Boxer Other, Consultant.
, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio ), Other, Consultant.
858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta ), Other, Consultant.
I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus ), Other, Consultant.
Novocure, Odyssey, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prolynx, Radiopharma Theranostics, Repare, resTORbio, Roche Other, Consultant.
Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals Other, Consultant.
Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera, Zai Labs, and ZielBio Other, Consultant.
S. V. Ulahannan,
Eisai, Astra Zeneca, IgM biosciences Other, Advisory board.
AbbVie Inc, Adlai Nortye, ArQule, Inc, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Ciclomed LLC, Erasca, Evelo Biosciences Inc, Exelexis, ExTheraMedical ).
G1 Therapeutics Inc, GlaxoSmithKline GSK, IGM biosciences, Incyte, Isofol, Klus Pharma Inc, Macrogenics, Merck Co Inc, Mersana Therapeutics, OncoMed Pharmaceuticals Inc., Pfizer, Qurgen ).
Regeneron Inc., Revolution Medicines Inc., Synermore Biologics Co, Takeda, Tarveda Therapeutics, Tesaro, Tempest, Vigeo Therapeutics Inc. ).
N. Lakhani,
Janssen Oncology Other, Consulting.
Alexo Therapeutics, Ascentage Pharma, BeiGene, Constellation Pharmaceuticals, Forty Seven, Loxo, Macrogenics, Merck, Pfizer, Regeneron, Apexian Pharmaceuticals, Coordination Therapeutics, Symphogen ).
CytomX Therapeutics, InhibRx, Incyte, Jounce Therapeutics, Livzon, Northern Biologics, Tesaro, Innovent Biologics, LAM Therapeutics, Ikena, Celgene, Shattuck Labs, Alpine Immune Sciences, Genmab ).
Odonate, Mersana, Seagen, Alpine Biosciences, Pharma, Helsinn Therapeutics, Ikena Oncology, Lilly, Sapience Therapeutics, Epizyme, Gilead, Glaxo Smith Kline, Tizona, Servier, Alkermes ).
KSQ, Repare Therapeutics, Biosplice/Samumed, Sapience Therapeutics, Life Sciences, Janssen, Arcus, Artios, BioNTech SE, Alkermes/Mural Oncology, Quanta Therapeutics, Circle Pharma ).
Day One Biopharmaceuticals, Revolution Medicines, ALX Oncology, Adcentrx, Astellas Pharma, Bright Peak Therapeutics, BioNTech SE, Bristol-Myers Squibb/Celgene, Roche, Treeline Biosciences ).
M. Barve,
1200 Pharma, A2A Pharmaceuticals, Abbisko, AbbVie, Inc., Agenus, Alterome Therapeutics, Alyssum, Amgen, Inc., Apollo Therapeutics, Aprea AB, Aptevo Therapeutics, Arcus Biosciences Inc. ).
Array BioPharma, Inc., Artios Pharma Limited, Arvinas Androgen Receptor, Astellas Pharma Global Development, Inc., AstraZeneca, Avenzo Therapeutics, Inc., BeiGene USA, Inc., BerGenBio AS ).
Bicycle Therapeutics, BioAtla, BioNTech SE, Bio-Path Holdings, Black Diamond Therapeutics, Boehringer Ingelheim, BriaCell Therapeutics, BridgeBio Oncology Therapeutics, Bristol-Myers Squibb ).
CanBas Co., Ltd., Carrick Therapeutics Ltd., Coherus BioSciences, Inc., Compass Therapeutics Inc., Context Therapeutics, Inc, CStone Pharmaceuticals, Cybrexa 2, Inc., Daiichi Sankyo, Inc., Dendreon ).
Dialectic Therapeutics, Inc., Doma Biopharmaceutical (Suzhou) Co.,Ltd., Dren Bio, Elevation Oncology, Elucida Oncology, Inc, EMD Serono, EpicentRx Inc, Epizyme Inc, Erasca, Eutilex, Exelixis Inc. ).
F. Hoffmann-La Roche Ltd (Genentech), Gan & Lee Pharmaceuticals, Genentech, Gilead Sciences, GlaxoSmithKline, Gradalis, GSK, Harpoon Therapeutics, Inc., HighField Biopharmaceuticals Corporation ).
Hutchison Medipharma LTD, HUTCHMED Limited, Iambic Therapeutics, Inc., IGM Biosciences, Inc, I-Mab Biopharma, Immune-Onc Therapeutics, ImmuneOnco Biopharmaceutics (Shanghai) ).
Immunovaccine Technologies, Immvira Pharma Co. Ltd, Impact Therapeutics, Inc., Incyte Corporation, Inhibrx, Inc., Ipsen, Jacobio Pharmaceuticals Co., Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ).
Klus Pharma, Inc., Kumquat Biosciences, Laekna Limited, LaNova Medicines Ltd, LigaChem Biosciences, Inc., Loxo Oncology, Mary Crowley, Medikine, Merck Sharp & Dohme Corp., Mersana Therapeutics, Inc., ).
Mirati Therapeutics, Inc., Molecular Templates Inc, Monte Rosa Therapeutics, Mundipharma Research Limited, Nektar Therapeutics, NeoImmuneTech, Inc., Nitto BioPharma, Inc., Novartis Pharmaceuticals ).
Numab AG, Nuvation Bio, Onconova Therapeutics Inc., ORIC Pharma, PEEL Therapeutics, Inc., Pfizer, Pionyr Immunotherapeutics, Prelude Therapeutics Inc, Protagonist Therapeutics, Inc. ).
Qilu Puget Sound Biotherapeutics Corporation, Qurient Co., Ltd., RAPT Therapeutics, Inc., Recursion Pharmaceuticals, Inc, Revolution Medicines, Inc., Sanofi, Sermonix Pharmaceuticals ).
Servier Pharmaceuticals, SillaJen Inc., Simcere (Jiangsu) Pharmaceutical Co, Sorrento Therapeutics, Inc., SpringWorks Therapeutics, Inc., Stemline Therapeutics, Inc., Step Pharma, SAS ).
Sumitomo Dainippon Pharma Oncology (SDPO), Surface Oncology, Inc., Sutro Biopharma, Inc., Suzhou Transcenta Therapeutics Co., Ltd., SynerGene Therapeutics, Synthorx, Takeda Pharmaceutical Co ).
Takeda Pharmaceutical Co (Subsidiary of Millennium), TESARO, Inc., Theratechnologies Inc, TransCode Therapeutics Inc, Vyriad, Xbiotech, Xencor Inc., Xilio Development Inc. ).
E. P. Hamilton,
Arvinas, AstraZeneca, BeOne Medicines, Boehringer Ingelheim, Boundless Bio, Bristol-Myers Squibb, Circle Pharma, Daiichi Sankyo, Gilead Sciences, Halda Therapeutics, Incyclix Bio, IQVIA, Janssen Other, Consulting.
Jazz Pharmaceuticals, Jefferies LLC, Johnson and Johnson, Lilly, Mersana Therapeutics, Novartis, Pfizer, Precede Biosciences, Pyxis Oncology, Roche/Genentech, Samsung Bioepis, Shorla Pharma Other, Consulting.
Stemline Therapeutics, Tempus Labs Other, Consulting.
Abbvie, Accutar Biotechnology, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Bicycle Therapeutics, Biohaven Pharmaceuticals, BioNTech, Compugen, Cullinan, Daiichi Sankyo, Dantari ).
Day One Biopharmaceuticals, Duality Biologics, Ellipses Pharma, Elucida Oncology, Exelixis, FujiFilm, Genmab, Gilead Sciences, H3 Biomedicine, Iambic Therapeutics, Immunogen, Inspirna, InventisBio ).
Jacobio, Jazz Pharmaceuticals, K-Group Beta, Kind Pharmaceuticals, Lilly, Loxo Oncology, Mabspace Biosciences, Mabwell Bioscience, Marengo Therapeutics, MediLink Therapeutics, Merck, Mersana ).
Novartis, Olema, Orinove, Orum Therapeutics, Pfizer, Pionyr Immunotherapeutics, Prelude Therapeutics, Profound Bio, Regeneron, Relay Therapeutics, Rgenix, Roche/Genentech, SeaGen, Shattuck Labs ).
Simcha Therapeutics, Stemline Therapeutics, Sutro, Systimmune, Taiho, Tesaro, TheRas, Treadwell Therapeutics, Verastem, Xadcera Biopharmaceutical, Zymeworks ).
B. Bashir,
Amgen, AstraZeneca, Avenzo, Artios, Bicycle Therapeutics, Boehringer Ingelheim, Elucida Oncology, Fate Therapeutics, Gritstone Bio, Ikena Oncology, Jazz Pharma, Johnson & Johnson Innovative Medicine ).
KAHR Medical, Kumquat Biosciences, Lyell Immunopharma, Merck, Pionyr Immunopharma, RasCal Therapeutics, Syros, Tarveda, Targeted Diagnostics & Therapeutics ).
Merck/ Eisai, Fate/ Ono Therapeutics, KAHR Medical, Tempus AI, Guardant Research Other, Advisory Board/Speaker’s Bureau.
H. M. R. Robinson,
Artios Pharma Ltd Employment, Stock Option.
J. B. Majithiya,
Artios Pharma Ltd Employment, Stock Option.
AstraZeneca Stock.
Crescendo Biologics Stock, Patent.
P. Costales,
Artios Pharma Ltd Employment, Stock Option.
S. V. Holt,
Artios Pharma Ltd Employment, Stock Option.
Mosaic Therapeutics Employment, Stock.
S. C. Skelton,
Artios Pharma Ltd Employment, Stock Option.
M. Roy-Luzarraga,
Artios Pharma Ltd Employment, Stock.
J. C. Bemis,
Litron Laboratories Employment.
D. Torous,
Litron Laboratories Employment.
S. Avlasevich,
Litron Laboratories Employment.
S. Barriga,
Artios Pharma Ltd Employment, Stock Option.
B. Harrop,
Artios Pharma Ltd Employment, Stock Option.
G. A. Langford,
Artios Pharma Ltd Employment, Stock Option.
Bicycle Therapeutics Stock, Patent.
I. Smith,
Artios Pharma Ltd Employment.
G. C. M. Smith,
Artios Pharma Ltd Employment, Stock Option.
AstraZeneca Stock.